Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer

International Journal of Molecular Sciences

SamG. Pappas¹  RichardA. Jacobson¹  MilesW. Grunvald¹  TimothyM. Kuzel²  Ashiq Masood² 

[1] Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA;Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA;

关键词: liquid biopsy;    pancreatic cancer;    cell free DNA;    circulating tumor DNA;   

DOI  :  10.3390/ijms21207651

来源: DOAJ

【 摘 要 】

Pancreatic cancer is a challenging disease with a low 5-year survival rate. There are areas for improvement in the tools used for screening, diagnosis, prognosis, treatment selection, and assessing treatment response. Liquid biopsy, particularly cell free DNA liquid biopsy, has shown promise as an adjunct to our standard care for pancreatic cancer patients, but has not yet been universally adopted into regular use by clinicians. In this publication, we aim to review cfDNA liquid biopsy in pancreatic cancer with an emphasis on current techniques, clinical utility, and areas of active investigation. We feel that researchers and clinicians alike should be familiar with this exciting modality as it gains increasing importance in the care of cancer patients.

【 授权许可】

Unknown